What happened

On Tuesday, October 27, the SEC's Small Business Capital Formation Advisory Committee met in Washington and gave Regulation Crowdfunding its own afternoon session. According to the SEC's announcement, the morning was set aside for IPO modernization, and the afternoon covered the current Reg CF framework, its successes and challenges, and whether policy changes could expand access to early-stage capital.

The agenda titles the 1:00 p.m. ET session "10-Year Anniversary of Regulation Crowdfunding" and names three speakers: Brian Belley, chief technology officer at Kingscrowd; Sherwood Neiss, principal at Crowdfund Capital Advisors; and Nicholas Tommarello, founder and CEO of Wefunder. That is an analytics provider, a policy advocate and a platform operator in one room.

One caveat on sourcing. The only post-meeting write-up I could find is a Wisevoter article dated October 28, and it reports no vote and no formal recommendation. The committee's own page lists no recommendation from this meeting. Its most recent adopted recommendations cover "Modernizing Market Access" (July 21 and August 6, 2026) and "Finders" (February 24, 2026), and the last Reg CF recommendation on that page is dated May 6, 2024.

So this is a hearing, not a decision. It still matters, because it puts the exemption's first decade on the record at the moment the SEC has a live request in front of it.

The request on the table

The vehicle is File No. 4-914, a petition asking the SEC to raise the Reg CF limit from $5 million to $20 million per 12-month period. Crowdfund Insider reported the filing in January, and the petitioner's side was represented on the October 27 agenda by Neiss, whose firm, Crowdfund Capital Advisors, is named in that coverage as the petitioner. The Wisevoter piece notes that the cap stands at $5 million after the 2020 increase from $1.07 million, and that participants at the 45th Annual Small Business Forum have also called for $20 million.

New comments in the file show who is lining up behind the idea. Two letters dated October 12 are worth reading because they come from operators, not trade groups.

John Calicchio of ICON Capital Group, an SEC-registered broker-dealer, argues that early-stage biotech, healthcare and medtech companies need substantial funding for clinical studies, regulatory submissions and commercialization, and that $5 million can fall short. Mark Stevenson of MedTech Syndicates makes a similar case: medical technology development, from prototype through clinical evidence and regulatory clearance, often needs more than $5 million.

Both describe the same workaround problem. Issuers that reach the limit split financing across exemptions, run additional offerings, or move to accredited-only rounds. Stevenson's phrase is that the cap "fragments" the raise rather than containing it, and he notes that non-accredited clinicians who helped validate a product can lose the chance to invest.

What the comment letters ask for beyond the number

The $20 million figure gets the attention, but the letters bundle three other asks that matter as much to anyone planning a raise.

First, inflation indexing. Calicchio asks that the limit adjust automatically so its purchasing power does not erode. The 2020 jump from $1.07 million to $5 million shows what a fixed number can do: it stays put until the SEC acts.

Second, conforming Exchange Act thresholds. Both letters support changes to Rule 12g-6 and related registration triggers, so that a successful raise does not push an early-stage company into full reporting. For a founder, this is the hidden cost of a bigger cap. A larger raise could pull a company toward periodic reporting sooner unless the thresholds move with it.

Third, keeping the guardrails. Calicchio lists disclosures, financial statement requirements, intermediary oversight, investor limits and antifraud protections as things to retain. Stevenson makes the same point about disclosure, investment limits and a regulated intermediary. Supporters are asking for a bigger box, not a looser one.

Stevenson also asks the SEC to grant the petition or fold the relief into its anticipated exempt offering rulemaking. That second route is the one to watch, because it would tie a cap change to a wider rewrite rather than a standalone amendment.

Opposition appears thin. Per Crowdfund Insider's headline on its comment-period coverage, most responses back the increase and one commenter, Shane Liddell of Smart Crowdfunding, wants the Commission to deny the request; I could not open that article, so treat the characterization as secondhand.

What it means for issuers and platforms

Many campaigns will never come near $5 million, so a higher cap would not help every issuer. It would help the post-revenue company that wants $10 million to $20 million from a community of customers and would otherwise stack Reg CF on top of Reg D or Reg A.

For those companies, the practical effects of a higher limit would be:

  • One offering document and one investor base in place of parallel exemptions, if the SEC leaves the other conditions alone.
  • A clearer path for non-accredited early backers to stay in later, larger rounds.
  • Greater scrutiny of disclosure quality, since bigger raises will draw bigger audiences and, potentially, more regulator attention.

For platforms, a larger cap raises average deal size and fee revenue per campaign, but also compliance exposure per campaign. That is likely why the intermediary voices in the file keep returning to investor protections.

The open question is registration. If the SEC raises the cap without adjusting the Exchange Act thresholds, successful issuers may find the extra capacity comes with reporting duties they did not plan for. Founders should read any proposal for its Rule 12g-6 language before they read its headline number.

What to watch next

  • SEC follow-through. Watch whether the committee turns the October 27 discussion into a formal recommendation, and whether the SEC's staff folds the petition into the exempt offering rulemaking Stevenson mentions.
  • The comment file. File No. 4-914 is public. New letters from platforms, investor advocates or state regulators would show whether the thin opposition holds.
  • Companion thresholds. Any proposal that touches Rule 12g-6, accredited-investor definitions or the Reg A and Reg D limits would change how a $20 million Reg CF raise compares with its alternatives.
  • Your own plan. If you expect to need more than $5 million within 12 months, model the split-exemption route you would use today, so you can compare it against a single higher-cap offering if one arrives.

This is information and commentary, not investment advice. Nothing here is a recommendation to buy or sell any security.

Sources